Plain-English translation of NCT07528586 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether cardiac magnetic resonance imaging (CMR)—a special type of heart scan—can detect heart damage earlier than current methods do in patients receiving anthracycline chemotherapy. Anthracyclines are powerful cancer-fighting drugs that sometimes harm the heart, but doctors don't always catch the damage early. This study wants to see if better imaging can catch these problems sooner, so doctors can help protect your heart during your cancer treatment.
Current heart monitoring methods like ECGs and blood tests sometimes miss early heart damage from this medication. By catching problems sooner, doctors may be able to adjust your care to better protect your heart while you're fighting cancer.
You likely qualify if…
You likely don't qualify if…
You'll have four heart imaging scans over about 15 months: one before your chemotherapy starts, one after you've received half your planned doses, one shortly after your chemotherapy ends, and one final scan a year later. Along with the imaging scans, you'll also have routine heart monitoring with ECGs and blood tests. Each visit takes a few hours, and the scans themselves are painless—you'll lie still inside the imaging machine while pictures of your heart are taken.
AI-generated summary from trial data · Aug 20, 2026 · Not medical advice
Germany